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     INTRODUCTION  
 Diabetes mellitus is a disorder of chronic hyperglycemia. It is caused by 
either deficient production or by the inefficient utilization of insulin, the major 
hormone responsible for lowering blood glucose levels in the body. Recently, more 
specific etiologies with molecular basis for specific types of diabetes are being put 
forth.  
  According to World Health Organization (WHO), Diabetes will be the 7th 
leading cause of mortality by 20301. India has  more people afflicted with diabetes 
than in any other country in the world, according to the details furnished by the 
International Diabetes Foundation. Thus, India is rightly named "the diabetes 
capital of the world" by Indian Heart Association2. Around 62 million Indians are 
currently affected by Diabetes, which comes to nearly 7.1% of India's adult 
Population. It is estimated that diabetes will affect 109 million individuals by 2035. 
Diabetes contributes to death in nearly 1 million Indians every year. Clinically 
evident diabetes becomes manifest around 42.5 years (i.e.) in the peak of 
productive years of life. All these data clearly expose the burden Diabetes imposes 
on the Indian economy. Adding to the misery, are the American Diabetes 
Association's reports that India is expected to see the greatest increase in newly 
diagnosed diabetic people by 20303 . The high incidence in Indians is ascribed to 
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the increased genetic susceptibility with growing middle class' high-calorie, low-
activity lifestyle and the differences in body composition.  
 Investigations for the early detection and management of diabetes are an 
ever growing field of medicine. The history rolls from the simple tests of detecting 
the glucose in urine done in early twentieth century to estimations of glucose in the 
blood, to the study of various enzyme activities to the latest investigations of 
immunological and molecular markers done nowadays to identify specific 
disorders in glucose metabolism.HbA1c is one such entity which has secured a 
pivotal place in the diagnostic criteria for diabetes. It was introduced as a marker of 
the glycemic control status over the past 2-3 months and has come a long way in 
being used as a diagnostic modality for diabetes approved by the WHO and 
American Diabetes Association (ADA). The recent identification of various pitfalls 
and confounding factors in the measurement of HbA1c has necessitated the review 
of its role. It is advised to be used with caution in certain population groups such as 
children, pregnant women, patients with hemolytic anemia or hemoglobinopathies. 
One such confounding factor  has been identified as anemia and the iron stores        
( ferritin) of the individual.4 The exact role of  anemia on Hba1c estimation is yet 
to be established as the studies conducted so far have given conflicting results. 
This study has been henceforth conducted to establish the effect of microcytic 
hypochromic anemia on HbA1c levels if any.    
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               AIM OF THE STUDY 
 
To analyze the effect of microcytic hypochromic anemia on HbA1c levels in non 
diabetic individuals. 
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             OVERVIEW 
DIABETES MELLITUS: 
INTRODUCTION: 
 The term Diabetes Mellitus (DM) is defined as a metabolic 
disorder with heterogeneous etiologies characterized by chronic 
hyperglycemia and disturbances of carbohydrate, fat and protein 
metabolism5 . The defect may be at various levels. Insulin secretion, 
action or sometimes both are affected. Thus it is the pathogenic 
process leading to hyperglycemia which forms the basis for the 
classification of diabetes. The two broad categories are designated as 
type 1 and type 2. Type 1 DM is the result of complete or near-total 
insulin deficiency. Type 2 DM is a heterogeneous group of disorders 
characterized by variable degrees of insulin resistance, impaired 
insulin secretion, and increased glucose production. Other etiologies 
for DM include specific genetic and metabolic defects in insulin 
secretion or action, mitochondrial abnormalities and a host of 
conditions that impair glucose tolerance.  
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The classification proposed by American Diabetes Association in 2011 
encompassing the various etiologies is as follows: 
Etiologic classification of diabetes mellitus 
 
HISTORY: 
 The history of diabetes dates back to ancient Egyptians describing clinical 
features very similar to Diabetes Mellitus 3000 years ago. The term "diabetes" 
meaning “siphon”, to explain the liquefaction of the flesh and bones 
into urine was first coined by Araetus of Cappadocia (81-133AD).7 He used this 
term while describing a disease with symptoms of excessive thirst and urination 
Table 1 : Classification of Diabetes Mellitus - ADA 20116 
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with  weight loss. Ancient Indians have first observed that urine and blood of 
diabetic patients were sweet. Later, in 1675, Thomas Willis added the word 
"mellitus" meaning "sweet" after rediscovering the sweetness of blood and urine. 
This  presence of excess sugar in urine and blood as a cause of their sweetness was 
confirmed in 1776 by Dobson. The identification of the role of liver in 
gluconeogenesis is an important accomplishment in the history of diabetes and this 
led to the conceptuation by Claude Bernard (France) in 1857 that excess glucose 
production causes diabetes. Extensive autopsy studies of diabetic patients 
concurrent with other developments led to the final identification of the etiological 
role of pancreas, especially the islets of Langerhans. Insulin principally designated 
as the isletin, as it was believed to be secreted by the islets was first discovered by 
a group of four people - John MacLeod, Fredrick Banting, Charles Best & J.B. 
Collip.7  They could also extract insulin in sufficient amounts from beef & pork 
pancreas and use it for lowering blood sugar levels in depancreatized dogs. The 
evolution of process of purification, stabilization, production in adequate amounts 
from non human sources and recombinant insulin production spanned over 8 
decades from 1920s. The long acting insulin was identified in 2001. 
EPIDEMIOLOGY:  
  According to WHO data, 347 million people worldwide are suffering with 
diabetes3. In 2014, the estimated global prevalence of diabetes was 9% among 
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adults aged 18 years and above. It was a leading cause of death, that in 2012, an 
estimated 1.5 million deaths were directly caused by diabetes. The burden of 
diabetes is deeply rooted in the low and middle income countries that more than 
80% of diabetes deaths occur in them. Wild et al 8 predicts the prevalence of 
diabetes to double globally from 171 million in 2000 to 366 million in 2030. The 
proposed increase is expected to be maximum in India with an estimated 79.4 
million diabetics . Diabetes and its complications have a serious impact on the 
economy of a country as it predominantly affects people of the work force.  
Fig: 1 WHO region wise distribution of Diabetes mellitus 
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INDIAN SCENARIO: 
 According to the model of four phases of health transition, manmade and 
degenerative diseases predominate while communicable diseases are in the 
decreasing trend in low and middle income countries such as India. A life 
expectancy bordering around 50-60 years and unhealthy lifestyles which promote 
lifestyle diseases like cardiovascular disease, diabetes and hypertension 
characterize this phase. There is an increase in the incidence and prevalence of non 
communicable diseases.  The low education levels and poor awareness of diseases 
and their complications in the low income countries exaggerate the impact on 
health of the population. 
 In India, which has sadly earned the distinction of being the “diabetes capital 
of the world”, diabetes is fastly reaching epidemic proportions with more than 62 
million diabetic individuals. In 2000, India (31.7 million) topped the world with 
the highest number of diabetic population superseding China (20.8 million) and the 
United States (17.7 million).  Most states in India have a prevalence rate of 10 %. 
Kerala tops the list having the highest incidence of 19.5% and  Kashmir valley the 
lowest at  6% 9.  ICMR-INDIAB study which was conducted in three states and one 
Union Territory has estimated that India is likely to have 62.4 million diabetic 
patients. There is another 77.2 million people in the pre diabetic group.  In a 
longitudinal cohort study done in Chennai, the incidence of diabetes was around 
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20.2 per 1000 person years among subjects who had normal glucose tolerance 
before. It was 64.8 per 1000 person years in those with pre-diabetes. 
 The prevalence of diabetes in urban areas varied between 10.9 % and 14.2%. 
The numbers were smaller in rural areas from 3.0% to 8.3%10. But, 
disturbingly, number of people detected with diabetes is increasing in rural areas 
recently. The likely explanation is the extension of urbanization and adoption of 
unhealthy lifestyles in the rural population.  
WHY ARE THERE MORE DIABETICS IN INDIA? 
 Apart from the conventional risk factors for diabetes present globally like 
urbanization, industrialization, globalization, other factors also play a pivotal role 
in contributing to the increased prevalence in Indians. Obesity, regional 
distribution of adiposity, increased proportion of body fat for the same body 
weight, fetal programming and genetic factors proffer to higher risk. In adults , the 
classical variables associated were age, BMI,  increased Waist Hip Ratio (WHR), 
sedentary life style , a family history of diabetes, , socio-economic status. The 
increased proportion of body fat due to visceral adiposity and a higher risk of 
diabetes for the same BMI as compared to the rest of the global population have 
made WHO recommending revised guidelines for Asian population. A BMI of  
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23–27.5 kg/m2 is at more risk for type 2 diabetes. A BMI of 27.5 kg/ m2 or higher 
is at high risk.   
 The other factors contributing to increased prevalence are:  
1) Changing dietary habits from the traditionally consumed diet in urban and rural 
areas. People consume up to 32% of daily energy requirement as fat. 
2) Widespread use of automobiles and decreased physical activity of the 
population that was once heavily dependent on farming and other manual labor. 
3) Increasing "screen time" due to the increasing education and awareness about 
the disease is another aspect to be given due place in causing increased incidence 
of diabetes11.  
 Apart from the modifiable risk factors as stated above, recent identification 
of new susceptibility locus at 2q21 by the Genome Wide Association Study 
(GWAS) is also being postulated to contribute. However, in a poly genetic disease 
like diabetes, no more than 10 % of incidence can be attributed to this genetic 
defect. 
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 Fig: 2 Estimated numbers of diabetic subjects in India9
 
 
Fig.3 Prevalence of Diabetes in India: ICMR-INDIAB study10
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Fig.4 Prevalence of Diabetes & pre diabetes in India: ICMR-INDIAB 
study (contd.)10 
                         
 Though type 2 diabetes is a disease of adults, according to new 
studies, risk factors start getting established even in childhood .The 
influences of early life including the intra-uterine period also 
contribute to the onset and progression of the disease. These factors 
are also contributing to the emergence of obesity and overweight as 
important public health problems in India. There is a reported 
prevalence of around 20-30% of metabolic abnormalities including 
dysglycemia (about 10%) and dyslipidaemia (25-40%) in urban socio-
economically advantaged school going children who is apparently 
healthy but obese or overweight. An increase in obesity prevalence is 
also apparent from the National Family Health Survey (NFHS) data. 
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From 11% in NFHS- 2 (1998-1999) prevalence of obesity has gone up 
to 15% in NFHS-3 (2005-2006)12.These people are at increased risk of 
developing diabetes and other obesity related problems in their future 
life. In the New Delhi Birth Cohort study, dysglycemia in later life was 
found to be inversely related to BMI and weight at 1 year of age. But, 
after 2 years of age, this relationship gets straight. An increase in BMI 
was associated with increased risk of diabetes. The study showed that 
the highest prevalence of diabetes and dysglycemia was in subjects 
who formed the lowest third of the group with respect to BMI at 2 
years and highest at an age of 12 years13. Thus it has been established 
that low birth weight as seen in majority of the Indian new borns and 
accelerated weight gain after 48 months are predisposing to adult onset 
glucose intolerance. 
ANATOMY OF PANCREAS: 
        Pancreas (meaning 'all flesh') is a glandular organ with both endocrine and 
exocrine functions. Situated behind the stomach, retroperitoneally, it secretes 
digestive enzymes through the exocrine part into the gut lumen. The endocrine part 
of pancreas, Islets of Langerhans lies embedded in the gland. It has three types of 
cells namely α, β and D cells and secretes insulin, glucagon, somatostatin, amylin 
into the blood stream and plays a vital role in glucose homeostasis. 
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  Fig: 4 Macro and micro anatomy of pancreas  
INSULIN SYNTHESIS AND SECRETION: 
 Insulin is produced in the islet cells as a single chain preproinsulin with 86 
amino acids. It is acted upon by proteolytic enzymes cleaving the signal molecule 
to pro insulin. Subsequent proteolysis cleaves C- peptide, α & β amino acid chains. 
α & β amino acid chains contain 21 & 30 amino acids respectively. Though insulin 
secretion is influenced by numerous factors like amino acids, ketones 
neurotransmitters and nutrients, glucose is the prime regulator. Entry of glucose 
into islet cells is mediated by facilitated transporter GLUT 2 . Glucose is utilized 
via the glycolytic pathways involving glucose-6-phosphate formation as the rate 
limiting step. ATP derived from glycolysis inhibits ATP dependent K+ channel 
causing depolarization of the cell. This depolarization causes opening of voltage 
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dependent Ca2+ channel causing calcium influx and insulin secretion. This occurs 
in a pulsatile manner occurring every 10 minutes with superimposed pulsations of 
higher amplitude occurring every 80-150 minutes. The ingested foods regulate the 
secretion of insulin through incretins secreted by neurotransmitter cells of the GI 
tract. GLP-1 analogues are the most potent incretins secreted by L type cells5. 
 Fig: 6 Mechanism of glucose mediated insulin synthesis 
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   Fig: 7: Insulin synthesis and secretion 
ACTION:  
 Once insulin is secreted into the portal system, approximately 50% is  
 taken up and degraded by the liver. The rest of the insulin gaining access to the  
systemic circulation binds to insulin receptor which has intrinsic tyrosine kinase 
 activity. Upon binding to insulin receptors, insulin causes stimulation of tyrosine  
kinase leading to auto phosphorylation of a subset of proteins called as Insulin  
Receptor Substrate (IRS) . They initiate a cascade of phosphorylation and  
dephosphorylation reactions accounting for the metabolic actions of insulin like  
increased uptake of glucose into skeletal muscles, liver and adipocytes.  
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 In skeletal muscle, glucose is either used up or stored as glycogen . In liver, 
glucose is converted to the storage form of glycogen and proteins while in adipose 
tissue, glucose is converted into fat.  Insulin is predominantly an anabolic hormone 
which not only stimulates uptake and utilization of glucose but also that of amino 
acids. 
PATHOGENESIS: 
TYPE 1 DIABETES MELLITUS: 
 Destruction of beta cells and absolute insulin deficiency are the 
pathognomonic features of type 1 DM. Various immunological, environmental and 
genetic factors interact and contribute to the destruction of beta cells and insulin 
deficiency. Auto antibodies are almost always detected in type 1 diabetic 
population though it may be absent in a few.  
 These people are born with normal population of beta cells which start to 
decline rapidly due to an auto immune insult secondary to an environmental or 
infectious organism. Having started, the process is sustained by beta cell specific 
molecule which is yet to be identified. Pathologically, it is this insulitis which 
characterizes type 1 DM. This process involves leucocytic infiltration of beta cells 
of islets causing destruction. Islet cell antibodies, activation of lymphocytes within 
islets, islet protein induced T cell proliferation, cytokine activation are the 
aberrancies noted in the humoral and cell mediated immunity After all beta cells 
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are destroyed, immunological process abates and islets become atrophic. The 
precise mechanism for islet cell death is yet to be known but involves apoptosis, 
formation of nitric oxide metabolites, CD8+ cell mediated cytotoxicity. The targets 
identified are insulin, Glutamic acid decarboxylase, and beta cell specific Zn 
transporter, ICA (Islet cell auto antibodies) -512 / IA-2. ICA assays are routinely 
being used to detect Type 1 DM.  Testing positive for ICAs combined with 
impaired insulin secretion to parenteral glucose testing poses the individual at a 
risk of >50% for developing type 1DM in another five years. It is noteworthy to 
mention that these auto antibodies are positive in 5-10% of type 2 DM and in a 
minority in GDM. In addition to these, environmental factors, entero viruses, 
rubella, coxsackie and nitrosurea compounds are also implicated. 
GENETIC FACTORS: 
 Genetic loci associated with increased susceptibility are linked to HLA 6 
mapping to regions encoding the class II Major Histo compatibility class 
molecules. As these molecules are the antigen presenting molecules to helper T 
cells, the differences in the amino acid composition alter the specificity of 
immunological response. HLA DR3 &4 haplotypes are most commonly present in 
type 1 diabetics.  The haplotype DQA1*0102, DQB1*0602 appear to protect people 
from type 1 DM (<1%) as it is extremely rare5. 
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   Fig: 8 Pathogenesis of type 1 Diabetes Mellitus 
 
TYPE 2 DIABETES MELLITUS:  
 It encompasses an array of disorders all of which share a common phenotype 
of hyperglycemia. Variable degrees of insulin resistance and insulin secretory 
defects play a central role in the pathogenesis of type 2 diabetes. Now the 
consensus is that absolute insulin secretory deficiency is preceded in years by 
insulin resistance. Overt diabetes develops following inadequate insulin secretion.  
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GENETIC FACTORS: 
 Genetic factors play an important role in pathogenesis of type 2 DM than for 
Type 1 DM as shown by the concordance rate of 70-90% in monozygotic twins. 
The disease is polygenic and multifactorial . The genes implicated are inward 
rectifying potassium channel, calpain-10, Zinc transporter, IRS, transcription factor  
7 like 2 gene . There is a 40 % risk of developing diabetes for an individual if both 
the parents are diabetic. 
PATHOPHYSIOLOGY: 
 Impaired insulin secretion, insulin resistance, abnormalities in lipid 
metabolism, excessive hepatic gluconeogenesis are all central to the development 
of  type 2 DM. Insulin resistance is the first to occur  and is relative in nature as it 
is  well compensated by supra normal levels of insulin . Insulin resistance occurs 
approximately ten to twenty years before clinical DM develops5. Once insulin 
resistance far exceeds hyperinsulinemia, impaired glucose tolerance develops as 
manifested by IGT. In due course, further decrements in insulin secretion is 
combined with excessive hepatic gluconeogenesis presenting as full blown 
diabetes with high fasting blood sugar levels. Further deterioration leads to beta 
cell failure and absolute insulin deficiency. 
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   Fig 9: Pathogenesis of type 2 Diabetes mellitus 
METABOLIC ABNORMALITIES: 
ABNORMAL MUSCLE METABOLISM: 
 Skeletal muscle is the most important organ concerned with glucose 
homeostasis as it accounts for approximately complete glucose utilization 
following glucose loads either by oral or parenteral routes. Unlike in tissues like 
brain, placenta and cornea, this process is insulin dependent. Thus insulin 
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resistance alters skeletal muscle utilization of glucose significantly contributing to 
post prandial hyperglycemia. There is decreased activity of Insulin receptor 
Substrate -1 activity and inositol phosphatase -3 activity in skeletal muscle. There 
is also an up regulation of negative regulators of insulin activity like plasma cell 
differentiation factor-1and phosphotyrosine phosphatases which dephosphorylate 
insulin receptor causing decreased action of insulin. 
ABNORMAL ADIPOSE TISSUE METABOLISM: 
 Adipose tissue mediated lipolysis is less effectively suppressed by insulin 
secondary to insulin resistance. This leads to increased circulation of free fatty 
acids. Adipokines are substances like resistin, adiponectin, leptin, TNF -α, retinol 
binding protein-4 that are secreted by adipocytes and regulate insulin sensitivity in 
an individual. These adipokines are reduced in obesity contributing to insulin 
resistance and diabetes5. 
ABNORMAL LIVER METABOLISM: 
 Increased hepatic gluconeogenesis is the process by which insulin resistance 
affects liver and contributes to hyperglycemia. In general, insulin suppresses 
hepatic glucose production by decreasing the flux of amino acids and free fatty 
acids and also helps in the conversion of glucose to glycogen. Insulin resistance 
makes this control lost contributing to reduced storage of glucose as glycogen and 
29 
 
increased fatty acid accumulation in the liver. Thus hepatic insulin resistance is an 
important factor contributing to both fasting and post prandial hyper glycemia.  
ABNORMAL METABOLISM IN BRAIN: 
 Though glucose utilization in brain is an insulin independent process, some 
neurons in the hypothalamic area controlling satiety express insulin sensitive 
GLUT-4.Hypothalamic insulin resistance contributes to reduced satiety occurring 
both as a cause and consequence of obesity. Also experimental studies have shown 
that hypothalamic resistance contributes significantly to hepatic insulin resistance. 
CLINICAL FEATURES: 
 The early symptoms of this disorder may be simple characteristic symptoms 
such as thirst, polyuria, weight loss, and polyphagia or rarely its most severe and 
potentially incurable forms as ketoacidosis or nonketotic hyperosmolarity. Often 
symptoms are not severe or may even be absent at the time of diagnosis though 
sufficient signs of end organ damage are evident clinically. Hyperglycemia 
sufficiently high enough to cause pathologic changes would have been present for 
a long time before the diagnosis is made. Consequently, diabetes often is 
discovered because of abnormal results from a routine blood or urine glucose test 
or because of the presence of a complication.  
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SCREENING: 
 The silent protracted course of diabetes necessitates the early and efficient 
diagnostic modalities for type 2 Diabetes and optimal screening of all high risk 
individuals. The ADA recommends screening all individuals >45 years for every 3 
years and screening individuals at an earlier age if they are overweight [BMI >25 
kg/m2] and have one additional risk factor for diabetes which can be enlisted as a 
family history of diabetes, physical inactivity, race, ethnicity, positive history of 
hypertension , HDL cholesterol< 35 mg/dL or Triglycerides more than 250 mg/dL,   
gestational diabetes mellitus, polycystic ovarian syndrome, or being previously 
diagnosed with IFG, IGT or A1c levels of 5.7- 6.4 %6. This screening is valid for 
type 2 DM only as a long asymptomatic period of hyperglycemia is rare prior to 
the diagnosis of type 1 DM. 
DIAGNOSIS: 
EVOLUTION OF DIAGNOSIS OF DIABETES MELLITUS: 
 The first test used to identify and quantitate the glucose in urine was first 
deployed by Avicenna, an Arab physician in 1000 A.D14. Noteworthy in the 
history of diabetes are the tests for the detection of sugar in urine by Benedicts test 
and Self Monitored Blood Glucose (SMBG) instruments by glucose peroxidase 
strip methods. OGTT, oral glucose tolerance test was first described in 1923 
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by Jerome W. Conn7. In 1969, the first portable glucometer was developed. HbA1c 
was discovered in the late 1960s as an incidental finding. 
 An ideal glucose monitoring device will be a device which is non invasive or 
minimally invasive, monitors blood glucose levels continuously, warns the patient 
of hypo or hyperglycemia and calculates data about hourly, weekly and monthly 
sugar values. Such a device is yet to come into existence. However, the diagnostic 
modalities for diabetes have come a long way from crude methods of urine 
analysis. The following is a review of the history. 
 Before 1975, patients were routinely monitored by serial urine sugar 
measurements done at home with occasional blood sugar values obtained from the 
laboratory14. Though simple, routine analysis of urine for presence and 
quantification of sugar/glucose is limited by several factors: 
1) Urine sugar estimation is affected by concentration, fluid intake, drugs ingested. 
2) The varying threshold of renal glycosuria especially in long standing diabetics. 
3) Absence of glucosuria does not equate to euglycemia as it is only a snapshot of 
blood sugar levels since the time of last void. 
Though former tests use reduction of copper ions, formation of enediols, the latest 
ones apply glucose oxidase - peroxidase method for detection of glucose in urine. 
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   Fig 10: Diastix urine glucose test strip & color chart       Fig11: semi quantitative urine   
       analysis by Benedict's method 
                  
 The results of DCCT trial15 has led to wide consensus viz. strict control of 
blood glucose levels is associated with significant differences in the outcome for 
type 1 diabetes and revolutionized the treatment criteria for diabetes15. It 
necessitated the formulation of specific treatment goals. This led to the necessity 
and hence the invention of new tests to monitor blood glucose levels. Serum 
monitoring of blood glucose (SMBG) came into use and took over the field of 
diagnosis and continue to reign. All these instruments principally use glucose 
oxidase peroxidase method. This method involves formation of hydrogen peroxide 
which reacts with horse radish peroxidase to form nascent oxygen. This nascent 
oxygen oxidizes orthotoluidine to form purple or violet color which is read by 
colorimetry.  It has expanded from laboratory based glucose estimations to self 
monitors used by the patients at home. 
FASTING PLASMA GLUCOSE (FPG): Fasting is defined as no caloric intake 
for at least 8 hours after which plasma glucose levels are measured. In a patient 
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with symptoms suggestive of hyperglycemia such as thirst, polyuria, unexplained 
weight loss, the diagnosis can be easily established by the fasting hyperglycemia. 
An elevated FPG warrants a diagnosis of DM and no further testing with OGTT is 
necessary. If the patient is asymptomatic or has only minimal symptoms and 
fasting blood or plasma concentrations are not diagnostic, an OGTT is often 
required to establish or refute a diagnosis of DM. 
 ORAL GLUCOSE TOLERANCE TEST (OGTT): 
 This is the Gold standard in the diagnosis of Diabetes mellitus though it is 
cumbersome as it takes nearly four hours to complete the test. The test is 
administered in the morning after an overnight fasting of 10 -16 hours. The patient 
should have been on unrestricted diet for 3 days before this test and should have 
had normal activity prior to testing. Heavy exercises should be avoided prior to 
testing. Smoking and other drugs known to affect sugar levels are to be avoided 
during testing period. After drawing blood for fasting plasma glucose level 
determination, subject is made to drink 75 g of anhydrous glucose or equivalent. 
Plasma or blood samples are drawn 2 hours after the test load. This test is used in 
diagnosis of gestational diabetes mellitus in women with high risk and can ideally 
be used in all but seriously ill, post trauma or with recent infections. 
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             Glucose tolerance normally varies from normal glucose homeostasis to 
impaired glucose homeostasis and diabetes mellitus, Using this blood glucose 
measurements, the spectrum of Glucose tolerance can be assessed using the fasting 
plasma glucose (FPG), the response to oral glucose challenge (OGTT). 
 NORMAL GLUCOSE TOLERANCE: 
A FPG <5.6 mmol/L (100 mg/dL), a plasma glucose <140 mg/dL (11.1 mmol/L) 
following an oral glucose challenge, and an HbA1C <5.6% define normal glucose 
tolerance.  
IMPAIRED GLUCOSE HOMEOSTASIS: 
It can be either Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance 
(IGT). IFG includes individuals with fasting plasma glucose concentrations of 100 
to 125 mg/dL (5.6 to <7.0 mmol/L). If an OGTT is performed consequently, some 
of these individuals will have IGT and some have diabetes. IGT cannot be defined 
on the basis of fasting glucose concentrations; an OGTT is needed to categorize 
such individuals. Although this group of individuals is at a higher risk of diabetes 
all will not develop.  
 
 
35 
 
DIABETES MELLITUS: 
DM is defined as the level of glycemia at which diabetes-specific complications 
occur rather than being defined just on the basis of deviations from a population-
based mean. The criteria are  
1) Symptoms of hyperglycemia plus random blood glucose measurements > 200 
mg/ dL.  
 2) Fasting plasma glucose levels > 126 mg/ dL or two hour post load plasma 
glucose levels > 200 mg/ dL during Oral Glucose Tolerance Test (OGTT). 
 3) HbA1 c > 6.5 %.  
To summarize, 
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HbA1c: 
EVOLUTION: 
 While blood & urine sugar estimation yielded results about the day-to-day 
glucose levels in the blood, the need for the objective assessment of long term 
control of diabetes popped up. Then came the discovery that proteins like 
Hemoglobin (Hb) were non enzymatically glycated in vivo depending on the sugar 
values.  Measuring these glycated proteins especially hemoglobin and serum 
proteins gave a new dimension in this field. The unique feature in the measurement 
of these proteins is that they can qualitatively assess the glycemic control over the 
past few weeks or months complementing the day-to-day testing. 
  Normal adult hemoglobin is predominantly comprised of HbA (α2β2) 
(97%) with HbA2 (α2δ2) (2.5%) and HbF (α2γ2) (0.5%) forming minor fractions. 
In 1958, Allen et al 14  discovered that Hb can be separated into at least three more 
minor Hb components more negative than Hb by cation exchange chromatography. 
The fractions were separated based on their electrophoretic properties. These 
fractions moved fast and were attributed to their glycated nature. Further works by 
Rabhar et al14 showed that these minor hemoglobin fractions were elevated in 
diabetics and hence the link was established. 
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  About 6% of total HbA is glycated in vivo as a function of circulating blood 
sugar. This is termed HbA1. This has fractions of  HbA1a1, HbA1a2, HbA1b and 
HbA1c. These fractions are differ slightly from the major component HbA0 .They 
are defined to be the 'fast hemoglobins' as they elude  fast in chromatography and 
migrate fast in electrophoresis. HbA1c makes the most of this fractions. HbA1c, 
varyingly called as the glucohaemoglobin, glycated hemoglobin has a stable adduct 
of glucose which is linked by covalent bonds to the N‐terminal valine of the β 
chain.  
The processes involved in the formation of HbA1c are as follows: 
1) To the N‐terminal of the β chain a glucose molecule binds. This glucose 
molecule is always in the open chain format, forming an aldimine (Schiff base)  
2) A more stable ketoamine is formed when this Schiff base undergoes an Amadori 
rearrangement. It is a non‐ enzymatic process which happens continuously in vivo. 
    Fig: 12 Steps involved in the formation of HbA1c 
38 
 
                                  
   Fig: 13 hemoglobin fractionation in electrophoresis 
 Hemoglobin glycated at sites other than the N-terminus of the Beta chain 
can also be formed e.g., epsilon amino groups on lysine residues. These fractions 
also make up the total glycated hemoglobin.  
 The concentration of HbA1c depends not only on the concentration of 
glucose in the blood but also on the life span of the erythrocyte. Because life span 
of erythrocytes in the blood is approximately 120 days, HbA1c represents the 
overall picture of the glucose concentration over the preceding 8–12 weeks. 
USE: 
 After the discovery of HbA1c and the process of glycation of proteins, a 
number of small studies were conducted correlating it to glucose measurements. 
All these studies established the fact that HbA1c, apart from being used as a 
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measure of glycemic control could also be used for diagnosis of diabetes.  The 
A1C-Derived Average Glucose (ADAG) study which was conducted in 643 
participants having a range of A1C levels is the first of its kind. It could provide a 
validated relationship between A1C and average glucose levels. This could be 
applied to a variety of diabetic types and patient populations16. HbA1c was 
recommended for clinical use in the 1980s and subsequently has become a 
diagnostic tool for DM. 
 HbA1c reflecting the average levels of plasma glucose over a period of past 
3 months can be performed at any time of the day and fasting status of the patient 
has no bearing on the values measured. As it excludes the influence of day-to-day 
variability of glucose values, and avoids the need for the person to fast and to have 
preceding dietary preparations, HbA1c is now the preferred test for assessing 
glycemic control in people with diabetes. Also these advantages make HbA1c an 
ideal tool for early identification and treatment which is being strongly advocated 
in the recent years considering the potential complications and the socio - 
economic consequences of diabetes.  Recognized as the gold standard parameter of 
diabetic survey now, it was successfully implemented in clinical practice in the 
1970s and 1980s and internationally standardized in the 1990s and 2000s. WHO 
first made a mention of the promising utility of HbA1c in diabetes care in 1985 
WHO report. 
40 
 
 International Expert Committee has published in 2009 the role of HbA1c in 
the diagnosis of diabetes17. The recommendations are as follows:  
1)  HbA1c to be used to diagnose diabetes at levels ≥6.5%. 
2)  If clinical symptoms and plasma glucose levels >11.1mmol/l (200 mg/dl) are 
not present, diagnosis should be confirmed with a repeat HbA1c test. A value of 
5.7-6.4 % is suggested as the high risk range and levels just below 6.5% indicate 
the presence of intermediate hyperglycemia, the precise lower cut-off point is yet 
to be defined. Considering the continuum of risk captured by the HbA1c assay, the 
International Expert Committee recommended that HbA1c levels between 6.0 and 
6.5% were at high risk for diabetes and might be considered for rigorous diabetes 
prevention interventions. 
 Larsen et al18 in his study assigned type 1 diabetic patients into two groups 
as treatment and control groups. HbA1c testing was done in both groups at 
specified intervals. But results were informed only to the treatment group. Other 
than this both groups were essentially identical in their management. They showed 
that HbA1c was significantly reduced in the treatment group. The awareness of 
Hba1c alone has led to change in the behavior of the patients and better control. 
The importance of HbA1c cannot be overstated than this. 
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 Though initially used as an indicator of past glycemic control it became a 
widely used measure of long standing complications of diabetes as close 
correlation could be drawn between HbA1c levels and fasting and post prandial 
glucose levels and micro vascular complication of diabetes. DETECT -2 was the 
first of the trials to establish such a relation. These findings were reinforced by 
numerous trials conducted later and it is now established that HbA1c can be used 
as a marker of micro vascular complication of diabetes.  DCCT has also defined 
the quantitative relationship between HbA1c and sugar values. A 1 % increase in 
Hba1c is equivalent to 35 mg% increase in plasma glucose15.  
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Fig 15: Relationship of HbA1c to risk of micro vascular complications - 
Diabetes Control Complications Trial (DCCT)15 
 
 
Fig: 16 Pictorial representation of correlation between HbA1c and blood glucose   
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 DISADVANTAGES OF HbA1C:  
 HbA1c analysis has its own disadvantages. The high cost, non availability, 
sophisticated instruments used, need for skilled personnel, variability and lack of 
standardization procedures among different assays are some of them. Apart from 
the above said technical issues, patient factors, kinetics of HbA1c, genetic, 
hematologic and illness-related factors altering the values of HbA1c are also 
known to influence the results19. The most common and important factors 
prevalent worldwide  affecting HbA1c levels are hemoglobinopathies (assay 
dependent), almost all types of anemia's and disorders associated with accelerated 
red cell turnover such as malaria and hemolytic conditions.  
 Fig: 17 Advantages and disadvantages of assays for glucose and HbA1c 
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FACTORS AFFECTING HbA1c ANALYSIS19: 
       In detail, some of the factors influencing HbA1c measurement are as  
follows: 
1. Erythropoiesis 
Increased HbA1c: Iron deficiency, Vitamin B12 deficiency, conditions associated 
with decreased erythropoiesis. 
Decreased HbA1c: Erythropoietin administration, Iron and Vitamin B12 
supplementation, reticulocytosis and chronic liver disease. 
2. Altered Hemoglobin 
Genetic and chemical alterations in hemoglobin structure: hemoglobinopathies, 
HbF, methaemoglobinemia,  
3. Glycation 
 Increased HbA1c: Alcohol ingestion, deranged renal parameters, decreased intra 
erythrocyte pH. 
Decreased HbA1c: Aspirin, vitamin supplementations mainly E and C, 
hemoglobinopathies, and increased intra-erythrocyte pH. 
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4. Erythrocyte destruction 
Increased HbA1c: Splenectomy (causing prolonged RBC survival.) 
Decreased A1c : hemoglobinopathies, splenomegaly, rheumatoid arthritis or 
antiretroviral drugs ribavirin and other drugs like dapsone causing decreased RBC 
survival. 
5. Assays 
Increased HbA1c: Jaundice, carbamylated haemoglobin, chronic opiate use. 
Decreased HbA1c: hypertriglyceridemia. 
RECENT ADVANCES: 
   There are a number of methods available for HbA1c assay. The most 
commonly used are cation exchange chromatography, immuno assay, affinity 
chromatography and capillary electrophoresis. The principle in all assays is the 
difference in charge between HbA0 and HbA1c and the differences between 
glycated and non glycated forms of hemoglobin.  The laboratories should use an 
assay with inter assay coefficient of variation of <4% (ideally<3%) and it should 
be calibrated against DCCT standards. The DCCT standard is a high performance 
liquid chromatography. 
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COMPLICATIONS OF DIABETES MELLITUS: 
 Apart from the life threatening acute complications like Diabetic Kato 
Acidosis and Hyperosmolar non Ketotic coma, the most difficult part in the 
management of diabetes is the development of long-term complications and their 
consequences. Complications can be either vascular or non vascular. Vascular 
complications can be either disease specific micro vascular complications like 
retinopathy, nephropathy or neuropathy or less specific macro vascular 
complication of increased atherosclerosis.   
 There are episodic complications that can be treated only to re -occur 
numerous times (e.g., infections, ulcers and other skin diseases) or progressive 
with relentless course (e.g., nephropathy). They usually begin with mild severity 
but progress over time resulting in damage to the organ and irreversible loss of 
functionality.  Other complications include dental disease, reduced resistance to 
infections such as influenza and pneumonia, macrosomia and other birth 
complications among pregnant women with diabetes. Both type 1 and 2 diabetic 
complications share similar complications but frequency or onset timing can vary 
and severity has no relation to types of diabetes.  
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MECHANISMS OF MICROVASCULAR COMPLICATIONS: 
 Sorbitol accumulation through aldose reductase mediated activation of 
polyol pathway and consequent osmotic stress is the major mechanism behind 
pathogenesis. Protein kinase C activation, formation of advanced glycosylation end 
(AGE) products through non enzymatic reaction, oxidative stress from accelerated 
free radical production and reactive oxygen species formation resulting in cellular 
injury are the postulated mechanisms responsible for formation of micro aneurysm, 
pericyte loss and thickened basement membrane . Another mechanism involved is 
the presence of excessive growth factors, including vascular endothelial growth 
factor (VEGF), transforming growth factor β and growth hormone probably 
secondary to hypoxia. 
RETINOPATHY: 
 This is the most common micro vascular complication of diabetes. Milder 
form of this disease includes formation of micro aneurysms, hemorrhages with 
lipid accumulation appearing in the margin of hemorrhages collectively called 
background / Non Proliferative diabetic Retinopathy (NPDR). These lesions do not 
cause visual impairment unless when located near macula. Over time, micro 
vascular changes progresses to Proliferative Diabetic retinopathy (PDR). Capillary 
block causes retinal ischemia leading to new vessel formation. These vessels are 
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fragile which may bleed causing profound vision loss. The subsequent fibrotic 
tissue formation leads to retinal detachment. Duration of diabetes, uncontrolled 
hyperglycemic status, concomitant hypertension, and smoking are all linked to the 
development and progression of retinopathy20. Non proliferative retinopathy 
warrants yearly follow up while proliferative retinopathy needs photocoagulation 
as treatment. 
 
  Fig: 18 Diabetic retinopathy- Proliferative and non proliferative 
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NEPHROPATHY: 
 This is the most common cause of End Stage Renal disease requiring 
dialysis in the western world. The hallmark of diabetic nephropathy, proteinuria 
predominantly albuminuria is a result of continuum of changes from normo 
albuminuria to microalbuminuria and macro albuminuria culminating in the 
development of End Stage Renal disease (ESRD)21. The pathological changes 
noted in the kidney are increased glomerular basement membrane thickness, 
formation of micro aneurysm, Kimmelsteil-Wilson bodies- mesangial nodule 
formation. The underlying pathophysiology is the same as that for retinopathy 
involving AGE products, polyol pathway activation, increased oxidative stress and 
protein kinase C activation.  The prevalence of diabetes is directly proportional to 
the duration of diabetes with incidence around 10 % in the first years to 50 % after 
two decades. Uncontrolled hyperglycemias, duration of diabetes are important 
factors contributing to the development of nephropathy. Hypertension is another 
factor the effect of which as a cause or consequence remains to be settled. Male 
gender, smoking, increased protein intakes are the other factors postulated to play a 
role in the pathogenesis. Treatment with drugs blocking RAAS system like ACE 
inhibitors, Angiotensin Converting Enzymes, Direct Renin blockers have shown to 
delay the progression of diabetic nephropathy in Type 2 Diabetic Patients but not 
in type 1 DM.    
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NEUROPATHY: 
 Neuropathic complications of diabetes occur in approximately 50 % of the 
population with long standing diabetes. Any type of neuropathy like 
mononeuropathy, polyneuropathy, mononeuritis multiplex, autonomic 
polyneuropathy can occur. The pathogenesis of neuropathy is same as that for 
retinopathy and nephropathy. The symptoms can also mimic any other form of 
neuropathy.  So it is always diagnosed after excluding other causes of neuropathy. 
Also the symptoms can be a spectrum ranging from no symptoms to mild 
paresthesias to grossly disabling.   
 A sensation of numbness, sharp pricking/burning pain, tingling sensation , 
that begins typically in the feet spreading proximally are the usual symptoms. 
Neuropathic pain is characteristically present at rest and gets worse at night. This 
pain may gradually subside and even eventually disappear when all the sensory 
neurons die. The sensory deficit usually persists with loss of ankle reflexes and 
abnormal position sense. Autonomic neuropathy manifests as anhydrosis, gastro 
paresis, diarrhea, erectile dysfunction, orthostatic hypotension, silent myocardial 
ischemia and even death.  As with any other micro vascular complication, the 
duration of diabetes and hyperglycemia are the proposed mechanisms behind 
neuropathy.  
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Table 2: Diabetic Neuropathy classification5 
   
 Of the many types chronic sensory motor distal symmetrical poly 
neuropathy is the most common type. Least common is the sensory type associated 
with episodic hyperglycemia. No drug has been proved in curing neuropathy 
though drugs like anti epileptics, tricyclic anti depressants are used. Optimization 
of glycemic control delays the progression.  
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MACROVASCULAR COMPLICATIONS OF DIABETES: 
 The central mechanism of macro vascular complication of diabetes is the 
process of accelerated atherosclerosis as a result of increased oxidative stress, 
increased platelet adhesion , hypercoaggulabilty, reduced nitric oxide formation 
and altered calcium homeostasis. 
 
CORONARY ARTERY DISEASE: 
   Diabetes is an independent risk factor for ischemic heart disease. Cardio 
vascular disease is the leading cause of mortality and morbidity in diabetics. The 
risk of myocardial infarction in a diabetic is equal to that risk in a non-diabetic 
individual who had MI so American Diabetes association has recommended 
considering diabetes as coronary artery disease risk equivalent than as a mere risk 
factor. This risk is high in women especially in post menopausal group when 
compared to men. Studies have shown that unlike micro vascular complications, 
stringent glycemic control did not alter macro vascular complications20. 
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TREATMENT: 
 ADA  has proposed stringent guidelines for treatment of diabetes. Glycemic 
Targets for No pregnant Adults with Diabetes are pre-prandial capillary PG 80-
130 mg/dL; Peak postprandial capillary PG <180 mg/dL and HbA1c values 
<7.0%.Individualized treatment goals are adopted based on Age/life expectancy, 
Co morbidities and known cardiovascular diseases, duration of Diabetes, episodes 
of hypoglycemia if any.  
 
LIFESTYLE MODIFICATIONS: 
 They form the principal modality of treatment irrespective of the stage and 
type of the disease. Abstinence from smoking and alcohol, healthy eating pattern, 
achieving and maintaining ideal body weight through medical nutrition therapy, 
aerobic exercises delays or even prevents the complications of diabetes. Also 
attainment of individualized lipid, BP goals help in delaying the onset of 
complications.  
PHARMACOLOGICAL THERAPY FOR TYPE 1 DM:  
 Insulin remains the most important part of the treatment. Patients are ideally 
treated with 3-4 daily doses of basal and prandial insulin. Newer insulin analogues 
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prevent dangerous hypoglycemic episodes. The other agents that can be used are 
pramilinitide (an amylin analog). Metformin, incretins like GLP-1 analogues, 
DPP4 inhibitors, and SGLT-2 inhibitors are also being investigated to be used in 
type 1 DM.  
 
PHARMACOLOGICAL THERAPY FOR TYPE 2 DM: 
 If not controlled by lifestyle modifications, metformin is the ideal initial 
agent of choice. Sulfonylureas, Thiazoledinidiones, GLP- 1 analogues are all added 
if metformin monotherapy fails to achieve desired glycemic target. Insulin is used 
if the patients are severely symptomatic at presentation or have very high values of 
blood sugar on detection. Also insulin remains the mode of treatment in times of 
acute stress like surgeries, severe infections, Diabetic keto Acidosis or Hyper 
Osmolol Non Ketotic Coma.   
  ANAEMIA: 
 Anemia is a condition in which either RBCs or their oxygen carrying 
capacity to meet the physiological needs is reduced. The needs may vary according 
to age, sex, growth phases, altitude above sea level, pregnancy status and thus 
varying cut offs are used to define anemia in various subgroups.  
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EPIDEMIOLOGY OF ANAEMIA: 
 Anemia is a major public health problem that affects populations in both rich 
and poor countries. It poses major consequences on human health as well as social 
and economic development. It is generally present in people in all stages of the life 
cycle, but is more prevalent in pregnant women and young children. Globally, iron 
deficiency remains the most significant contributor to the onset of anemia as to the 
extent that Iron Deficiency Anemia (IDA) and anemia are often used 
synonymously23.  Even the prevalence of anemia has often been used as a proxy 
for IDA. 
  Though the proportion of cases of anemia contributed by iron deficiency is 
exactly estimated in only few countries, it is generally assumed that 50% of the 
cases are due to iron deficiency. The proportion varies among different population 
groups and in different areas with local conditions influencing it.  The increased 
prevalence of IDA is due to a number of risk factors rampant in the economically 
under- privileged and even in economically well developed countries like low 
intake of iron, phytate rich diet causing reduced iron absorption, and period of life 
when iron requirements are especially high like pregnancy, early stages of growth, 
puberty not being given adequate iron supplementations. The presence of co-
existent micronutrient deficiencies, including vitamins A and B12, folate, 
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riboflavin, and copper aggravates the problem. Numerous other factors can be 
enlisted to be contributing significantly to anemia: 
1) Poor purchasing power, illiteracy, ignorance regarding nutritional value of 
available cheap food 
2) Cultural taboos, superstition and parasitic infestations of hookworms, ascariasis, 
and schistosomiasis 
3) Discrimination faced by women eating only the 'last food' or the remaining food, 
heavy blood loss during menstruation. 
4) Acute infections like malaria and chronic infections including cancer, 
tuberculosis, and HIV can also lower blood Hb concentrations.   
5) The presence of hemoglobinopathies in certain populations23.  
 As the optimal values of Hb varies among people in different phases of life, 
WHO used various Hb thresholds to classify individuals living at sea level as 
anemic. The threshold and the prevalence of anemia are as follows: 
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Table 3: Hb threshold used to define anemia according to WHO23  
 
  Table 4: Global prevalence of anemia and number of population affected 
 
 
 Estimates from various countries were combined to calculate the estimates at 
the global level. This pooled data were also extended to the WHO region for 
women and preschool-age children by considering the weight given by these 
estimates to the population it represented. South East Asia and Africa top the 
WHO regions in anemia prevalence with values of 45.7% & 47.5% respectively. 
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INDIAN SCENARIO: 
 While WHO estimates provide a clue about the global picture, data from 
NFHS (National Family Health Survey -3) provide estimates about the burden IDA 
poses on the country. In India, anemia is more than twice prevalent in women than 
men. Half of these anemic women suffer from moderate to severe anemia. As 
expected, anemia is much more prevalent among pregnant women. In Adolescents 
and school- going children group, half of them are anemic. Though anemia is a 
common problem of both urban and rural areas, rural areas have a marginally 
higher percentage. But thanks to the various measures by the government and the 
spread of education, the prevalence of severe anemia is decreased. Iron deficiency 
remained the single most common cause of anemia. 
Table 5: Prevalence of anemia according to severity in urban and rural population 
according to NFHS -3 data 12 
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Fig 19: Pictorial representation of the prevalence of anemia according to NFHS -3 
data12 
 
 
 
 
 
Fig 20: Prevalence of iron deficiency anemia according to NFHS 312 
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CLINICAL MANIFESTATIONS: 
 The various symptoms of anemia results from hypoxia and the body's 
response to it. A variable presentation ranging from asymptomatic to mild 
symptoms of lassitude to severe symptoms of tachycardia with palpitations and 
pounding in the ears, headache and even classical pain of angina pectoris may all 
occur in patients who are severely anemic. 
CLINICAL MANIFESTATIONS THAT MAY BE UNRELATED TO 
ANEMIA 
• Decreased work performance 
• Headache  
• Paresthesias and other neurologic symptoms 
• Oral And Nasopharyngeal Symptoms 
• Dysphagia  
• Menstrual bleeding  
• Pica: Restless Legs  
• Hair Loss 
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CLASSIFICATION OF ANAEMIA: 
 Anemia can result from increased RBC destruction (hemolysis), 
decreased production or blood loss. This serves as a basis for classification 
of anemia. Also the next important criteria for classification is the ability 
of the bone marrow to compensate for anemia quantified as Reticulocyte 
count which is usually <1 % Combining these two parameters, anemias are 
classified as follows: 
 
Fig: 21 Algorithm for the physiologic classification of anmeia5 
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 The morphological classification of anemia as normocytic, microcytic, or 
macrocytic often correlates with the cause of anemia. The degree of 
hemoglobinisation reflected in the color of the cells (normochromic or 
hypochromic)-and the shape of the cells are the other indices used to classify 
anemia.  Visual inspection of peripheral smears can be used as a subjective 
measure of classifying anemia while they are quantitatively expressed through the  
following RBC indices:  
• Mean cell volume (MCV):  average red cell volume, expressed in 
femto liters (fL).  
• Mean cell hemoglobin (MCH): the average hemoglobin content 
(mass) per red cell, expressed in picograms (pg) 
• Mean cell hemoglobin concentration (MCHC): the average 
hemoglobin concentration in a given volume of packed red cells, 
expressed in grams per deciliter (g/dL) A lower MCH and MCHC 
show hypochromia. 
• Red cell distribution width (RDW): the coefficient of variation of 
red cell volume. Red cell volume distribution width (RDW) 
reflects the variation in the size of Red Blood Cells. 
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Table 6: Normal adult Red Blood Cell indices25 
 Units Men Women 
Hemoglobin (Hb) g/dL 13.6-17.2 12-15 
Hematocrit (Hct) % 39-49 33-43 
Red blood cells(RBC) *106/ mm3 4.3-5.9 3.5-5.0 
Reticulocyte count    
Mean corpuscular 
volume(MCV) 
fL 76-100 76-100 
Mean corpuscular Hemoglobin 
(MCH) 
Pg 27-33 27-33 
Mean corpuscular Hemoglobin 
concentration (MCHC) 
g/dL 33-37 33-37 
Red cell distribution width 
(RDW) 
 11.5-14.5 11.5-
14.5 
 
A lower than normal MCV (<80) - Microcytosis  
A higher MCV (>100) - macrocytosis.  
A lower MCH and MCHC values indicate under hemoglobinoisation- 
hypochromia 
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 Thus microcytic hypochromic anemia is defined as a condition where 
predominantly RBCs which are small and under hemoglobinized circulate in the 
blood. Most important cause is Iron Deficiency Anemia.  
         
   
 But there are also other causes which can cause microcytic hypochromic anemia. 
Table: 7 List of conditions associated with microcytic anaemia24 
Thalassemia & Hemoglobinopathies 
Β-Thalassemia Major 
Β-Thalassemia Minor 
δΒ-Thalassemia Major 
α -Thalassemia Major 
HbE trait 
Hb H disease 
Homozygous Hb E disease 
Blockade of heme synthesis caused by chemicals 
Lead 
Pyrazinamide 
Isoniazid 
Other disorders 
Sideroblastic anemia 
Hereditary sex linked 
Idiopathic acquired 
Anemia of chronic disease 
Hb Lepore trait  
Fig: 22 Microcytic Hypochromic anemia 
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BACK GROUND FOR THE STUDY 
 There are a number of studies analyzing the effect of microcytic anemia on 
HbA1c measurements. These studies have come up with conflicting results. Some 
have shown a positive correlation while some have shown a negative correlation.  
 Kim et al26 conducted a study where the effect of iron deficiency on HbA1c 
distribution among non diabetic adults was investigated. This study spanned over a 
period of 7 years of the National Health and Nutrition Examination Survey 
(NHANES). A cut point of < 5.5% vs ≥5.5% was used to study the distribution of 
HbA1c values as the recommended cut point was <6.5% vs. ≥6.5%. Of the 6,666 
participants, the prevalence of Iron Deficiency Anemia (IDA) was almost equal in 
the male and female populations at 33% and 30% respectively though iron 
deficiency was much more common in females at 13.6% when compared to 1.6% 
in males. The HbA1c values were 5.33% in iron deficient population and 5.27% in 
non-iron deficient population. The difference in these values were stastically 
significant (p=0.002) after adjusting for ethnicity and sex. Women belonging to 
reproductive age group had an increase in mean HbA1c from <5.5% to 5.5–6.0%. 
Thus the authors were of the conclusion that after adjusting for age and ethnicity, 
the HbA1c were elevated in iron-deficient individuals. 
  
66 
 
 Ford et al27 also evaluated 1999–2002 NHANES data. The Iron deficient 
anemic population and iron sufficient participants who were both diabetic and non 
diabetic were included in the study.  Non-diabetics with low Hb but sufficient iron 
levels had reduced HbA1c values (5.16%) than the participants who had normal 
values of both Hb and iron (5.31%), p<0.001. Thus this study identified a positive 
correlation between low Hb and HbA1c. They could also identify an inverse 
correlation between iron levels and HbA1c. HbA1c values were raised in 
participants with normal Hb but deficient iron stores. This was stastically 
significant from HbA1c value in normal counterparts (5.39% [35 mmol/mol], 
p=0.061). All non diabetic participants with higher values of Hb had a higher 
HbA1c values. The mean HbA1c was 5.18% (33 mmol/mol) at Hb <100 g/l while 
it was 5.50% (37 mmol/mol) at Hb >170 g/l. The largest impact was seen in 
HbA1c <5.0% group. They inferred that caution should be exercised when using 
HbA1c values near diagnostic cut points in the setting of anemia. Hb values were 
expected to change HbA1c a value by approximately 0.2 % (2.2 mmol/mol).This 
change is more noticeable in especially at the two ends of the spectrum of Hb 
levels. 
 Hardikar et al28   study is the first of its kind in India. Young adults 
belonging to Pune Children’s Study cohort were the participants. This cohort 
follows children born between 1987 and 1989 in the King Edward Memorial 
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Hospital (KEMH), Pune. This study made a comparison between HbA1c and 
OGTT determined diabetes rates in this cohort and scrutinized the hematological, 
nutritional and other factors influencing HbA1c concentration. Approximately one 
third of the population was anemic .43.6% had microcytic anemia while 2.5% had 
macrocytic anemia. More number of people was diagnosed with diabetes or 
prediabetes when an HbA1c criterion was used than by the gold standard OGTT 
(25.9% vs. 10.4%). The iron deficiency was much more prevalent and ferritin 
levels low in the participants classified byHbA1c as prediabetic or diabetic when 
compared with the normal group. The hematological parameters that were relevant 
to higher HbA1c levels were erythrocyte microcytosis, low MCH, low MCHC, and 
high RDW. The author proposed that there was an increased potential for 
misdiagnosis of diabetes and prediabetes in iron-deficient populations when 
HbA1c values alone are used. Iron deficiency induced alterations in the quaternary 
structure of the hemoglobin molecule and increased glycation of the b-globin chain 
was the likely explanation offered yet the role of uninvestigated genetic and 
environmental factors, influencing erythrocyte dynamics could also have been a 
contributing factor. 
 Son and others 29conducted a study in 329 non diabetic Korean participants. 
After performing OGTT, participants were categorized as normal, prediabetics or  
diabetics.  HbA1c levels in anemic and non-anemic participants were then 
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compared. In the normoglycaemic group, HbA1c values were not different in 
anemic and non-anemic groups. Anemic participants of the prediabetes group had 
higher HbA1c values when compared with controls (p=0.05). There was a 
borderline significance in the diabetes group. The investigators could not 
hypothesize as to why decreased erythropoiesis and altered red blood cell life span 
affect glycosylation of hemoglobin. A drop in the specificity of HbA1c to 81.1% 
was noted in the anemic group than in the non anemic group. Though the sample 
size was small and anemia types were unclassified, the authors could still establish 
a variation in HbA1c. 
 Shanthi30 and others studied the difference between HbA1c values in 50 
individuals with Iron deficiency anemia and nonanemic healthy controls both of 
them not known to have diabetes previously. Though there was no stastically 
significant difference between the fasting and post prandial glucose values a 
difference could still be made out between the HbA1c values of IDA and non 
anemic healthy groups. HbA1c values were significantly higher in the IDA group 
(mean 7.6±0.5% [60±5.5 mmol/mol]) compared with the control group (5.5± 0.8% 
[37±8.7 mmol/mol]; p<0.001. The authors differed in their hypothesis for the 
increased HbA1c in Iron Deficiency Anemia from others leading to a reduced half-
life of erythrocytes than elongations proposed by others though there was a 
69 
 
concurrence in the idea of Iron deficiency changing the quaternary structure of Hb 
molecule increasing glycation. 
 As the studies stated above have tried for establishing the difference in the 
HbA1c values in anemic and non anemic population, upcoming reviews are the 
reviews of the studies which after evaluating the difference in the levels of HbA1c 
proceeded for evaluating the effects of treatment/ iron supplementation to resolve 
anemia and aftermath of the supplementation on HbA1c. 
 Coban and others'31 study comprised of 100 participants - 50 had IDA while 
the rest 50 were healthy controls chosen after matching for age and sex.  Patients 
with IDA were given oral supplementation of   ferrous sulphate 100 mg a day for 3 
months. HbA1c values dropped significantly after iron treatment (p<0.001).This 
study suggests that iron deficiency must be corrected before using HbA1c for 
making a diagnostic or therapeutic decision 
 Sinha et al32 came up with a study which contradicted the other results in 
that HbA1c and absolute HbA1c levels increased after correction of anemia. This 
study conducted in Lok Nayak hospital, New Delhi included administering iron 
supplementation to 50 participants with IDA and serial monitoring of the 
erythrocytic indices while the erythrocytic indices were measured only once in 
controls. A noteworthy attempt of estimation of absolute HbA1c was made in this 
study.  Though the authors could not correct the anemia completely, mean HbA1c 
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after 2 months (5.9±0.6%) had significantly raised from the baseline (p<0.01).A 
significant increase was observed in the absolute HbA1c levels at 2 months after 
treatment (0.29g/dl vs. 0.73 g/dl, p<0.01).This study found decreased HbA1c 
levels at baseline and a rise in HbA1c with iron supplementation; these results 
were in complete contrast to the majority of other studies. The results were not 
explained. . 
 While the above mentioned studies analyzed the relation between (HbA1c) 
and iron status in type 2 diabetes mellitus (DM) Tarim et al 35 investigated the 
relationship between hemoglobin A1C (HbA1c) and iron status in type 1 diabetes 
mellitus. This study also included HbA1c analysis in diabetic patients who had 
insufficient iron stores. All iron deficient patients were treated with iron at 6 mg/kg 
per day for a period of 3 months. The study's conclusions were that among type 1 
DM patients with similar level of glycemia, iron deficiency anemia is associated 
with higher concentrations of HbA1c. This study also established that iron 
replacement therapy leads to a drop in HbA1c   values in both diabetic and non-
diabetic patients and the consideration of the iron status before making any 
therapeutic decision based on HbA1c holds good in type 1 DM also. 
 Having conflicting results from previous studies, this study was principally 
conducted to establish the role of microcytic hypochromic anemia on Hba1c levels 
in non diabetic individuals if any.  
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MATERIALS AND METHODS 
 This study was done at Government Royapettah Hospital, Chennai for a 
period of six months. The study was done after procuring informed written consent 
from all the participants involved. Clearance was obtained from the Ethical 
Committee of the Government Kilpauk Medical College & Hospital, Chennai. 
               STUDY DESIGN  
 The study design is a case - control study. 
               POPULATION 
 The study population included 100 people who attended the Dept. of Internal 
Medicine OPD in Govt. Royapettah Hospital and inpatients in the same hospital.  
           INCLUSION CRITERIA  
 50 non diabetic patients known to have microcytic hypochromic anemia are 
chosen as cases and 50 healthy age and sex matched individuals are chosen as 
controls. HbA1c levels in both the populations are compared.  
Microcytic hypochromic anemia is defined as: Hb--< 13 g/dL in males; < 12g/dL 
in females; RBC count< 4,50,000 in males; < 3,50,000 in females; MCH< 27 pg & 
MCHC< 33g/dL ;MCV<76 fl having microcytic hypochromic anemia in peripheral 
smear study.   
Healthy controls are defined as non anemic population with normal red cell 
indices and normal peripheral smear study.  
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      EXCLUSION CRITERIA 
• Confirmed cases of diabetes with one  or more of the following: 
H/O diabetes or taking medications, H/o symptoms related to 
diabetes with FBS>126 mg/dL & PPBS >200 mg/dL. 
• H/O acute blood loss, hemolytic anemia, hemoglobinopathies, 
recent surgery.  
• H/O kidney disease, liver disease or any major systemic illness.  
• H/O pregnancy and people with amenorrhea testing positive in 
urinary pregnancy test.  
• H/O endocrinopathy with effects on glucose tolerance 
• H/O blood transfusion in the past two months 
• Patients with blood urea levels greater than 20 mg/dL or with 
serum creatinine levels greater than 1.2 mg/dL (male patients) or 
0.9 mg/dL (female patients) were excluded. 
    METHODOLOGY: 
 50 non diabetic patients known to have microcytic hypochromic anemia 
were taken as cases. Age- matched healthy participants were taken as the controls. 
Both were chosen from the inpatient and outpatient departments of the hospital. A 
detailed history regarding age, sex, occupation, diet, menorrhagia and 
anthropometrical measurements made. 
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 After obtaining their consent, blood was drawn and the following parameters 
done: 
HEMOGLOBIN LEVELS: 
MCV: 
MCH: 
MCHC: 
RDW: 
 PLATELETS: 
ERYTHROCYTES: 
WBC: 
SERUM FASTING AND POSTPRANDIAL GLUCOSE LEVELS: 
SERUM CREATININE: 
HBA1C: 
ABSOLUTE HBA1C 
Evaluation of the Hemogram was done using sysmax automated cytology analyzer. 
HbA1c was analyzed using turbidimetric immunoinhibition. 
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STASTICAL ANALYSIS 
 
 
The results obtained were analyzed using SSPS software. 
For all practical purposes, anemia defined in the analysis is to be considered as 
microcytic hypochromic anemia as defined above and healthy as healthy age and 
sex matched controls.  
 
ANEMIA- DISTRIBUTION AND CHARACTERISTICS 
 
 AGE DISTRIBUTION AND MICROCYTIC HYPOCHROMIC ANEMIA 
 
 
 
 
AGE 
GROUP(years) 
ANEMIA   
TOTAL 
 
 
P VALUE 
ANEMIC HEALTHY 
12-20 27 
(42.9%) 
36 
(57.1%) 
63 
(63%) 
 
 
 
 
 
≥0.05 
 
21-40 
 
 
13 
(65%) 
7 
(35%) 
20 
(20%) 
 
41-60 
 
 
7 
(58.3%) 
5 
(41.7%) 
12 
(12%) 
 
Above 60 
 
 
3 
(60%) 
2 
(40%) 
5 
(5%) 
 
 
 
 
77 
 
The analysis shows: 
• Of the 100 participants(50 cases and 50 controls) in the study, the 
highest percentage of participants 63% are  in the age group of 12-20 
years, 20%  are in the age group of  21-40 years, 12% are in the 41-60 
years age group and 5% are in the age group of above 60 years. 
• There are  27 anemic patients in the 12-20 age group, 13patients 
in the 21-40 age group , 7 patients in the 41-60 years and 3 anemic 
patients in the age group of above 60 years. 
• There are 36 healthy persons in the 12-20 age group, 7 healthy 
persons in the 21-40 age group, 5 healthy persons in the 41-60 years and 
2 healthy persons in the age group of above 60 years. 
 
12-20 YEARS  
63%
21-40 YEARS
20%
41-60 YEARS
12%
>60 YEARS
5%
AGE- WISE DISTRIBUTION  OF THE    
PARTICIPANTS 
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SEX DISTRIBUTION AND MICROCYTIC HYPOCHROMIC ANEMIA 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
• Out of the 100 participants in the study, 76 are females and 24 
are males. 
• Out of the 24 male participants, 10 (41.7%) are anemic and the 
rest 14(58.3%) are  healthy controls 
• Out of the 76 female participants, 40(52.6) are anemic and the 
rest 36(47.4%) are healthy controls. 
 
54%
26%
14%
6%
AGE- WISE DISTRIBUTION OF 
ANEMIA
12-20YRS 21-40 41-60 Above 60
 
 
SEX 
 
 
 
ANEMIC 
 
 
HEALTHY 
 
 
TOTAL 
Male 10 (41.7%) 
14 
(58.3%) 
 
24 
(24%) 
Female 40 (52.6%) 
36 
(47.4%) 
 
76 
(76%) 
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• Male anemic patients -10 make up 20.0% of the total anemic 
population while 40 female anemic patients make up the rest. 
• This  analysis can be shown pictorially as                                                        
 
 
 
 
 
BMI AND ANEMIA 
 
 
 
 
 
 
 
 
From the analysis,  
• The mean BMI in the anemic population is 19.91 with S.D .3.7  
• The mean BMI in the healthy controls  is 22.51 with S.D. 3.0 
 ANEMIA MEAN±S.D P VALUE 
BMI 
 
Anemic 19.91±3.7 
< 0.001 
Healthy 22.51±3.0 
Sex 
Female Male 
Count 
50 
40 
30 
20 
10 
0 
anemia 
       anemic 
         healthy 
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• The difference in the mean BMI between two groups is stastically 
significant (p <0.001) 
• It is pictorially represented as  
 
 
 
 OCCUPATION AND MICROCYTIC HYPOCHROMIC ANEMIA 
 
 
 
OCCUPATION 
 
ANEMIA 
ANEMIC HEALTHY 
 
Student 
Count 29 34 
% within 
Occupation 46% 54.0% 
% within anemia 58.0% 68.0% 
 
House wife 
Count 7 3 
% within 
Occupation 70.0% 30.0% 
% within anemia 14.0% 6.0% 
 
Employed 
Count 14 13 
% within 
Occupation 51.9% 48.1% 
% within anemia 28.0% 26.0% 
  
  
18.5
19
19.5
20
20.5
21
21.5
22
22.5
23
anemia healthy
BM
I
BMI AND ANEMIA
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The analysis of results shows that  
• Majority of the participants of the study are students (63%). Out 
of these 63 students, 29 (46%) have anemia. 
• The next majority of the group involved is the employed people 
(27%) with 14 (51.9% ) being anemic and the rest 13(48.1%) healthy.  
• The anemic patients of these two groups constitute a total of 43 
(86 %) cases of anemic patients included in the study.  
THE DISTRIBUTION OF ANEMIA IN VARIOUS 
OCCUPATIONS:
 
 
 
Occupation 
Employed House 
wifes 
Students 
Count 
40 
30 
20 
10 
0 
 
ANEMIA  
 anemia 
healthy 
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 MENORRHAGIA AND MICROCYTIC HYPOCHROMIC ANEMIA 
 
 
 
  
 
 
•    The results on analysis show that out of the 76 female participants, 
47 have menorrhagia 
•    Out of the 47 menorrhagic participants, only 25(53.2%) had anemia 
while the rest 22(46.8%) are healthy. 
•    But out of 29 participants who did not have menorrhagia, 
15(51.7%) are anemic.  
•    The anemic menorrhagic participants 25 constitute 62.5 % of the 
total anemic patients.  
•    The association between menorrhagia and anemia is not stastically 
significant. 
 
MENORRHAGIA 
 
 
ANEMIA 
ANEMIC HEALTHY 
Yes 
 
 
 
 
 
 
 
 
 
 
Count 25 22 
% within Menorrhagia 53.2% 46.8% 
% within anemia 62.5% 61.1% 
No 
 
Count 15 14 
% within Menorrhagia 51.7% 48.3% 
% within anemia 37.5% 38.9% 
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 DIET AND ANEMIA 
 
 
 
DIET 
 
ANEMIA 
TOTAL 
 
P VALUE 
 ANEMIC HEALTHY 
 
 
Vegetarian 
 
 
 
8 
(61.5%) 
 
5 
(38.5%) 
 
13   
 
>0.05 
 Non Vegetarian 
 
 
42 
(48.3%) 
 
45 
(51.7%) 
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The analysis of results shows the following: 
• In the study, non vegetarian participants far outnumber the 
vegetarians. 
• Out of the 87 non vegetarians, 42 (48.3%) are anemic while 45 
(51.7%) are non anemic. 
• Out of the 13 vegetarians, 8 (61.5%) are anemic.  
• The results can be pictorially  represented as  
          
 
NON 
VEGETARIAN
87%
VEGETARIAN
13%
DIET DISTRIBUTION OF PARTICIPANTS
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 RED CELL PARAMETERS AND ANEMIA 
 
 
SEX 
 
 
ANEMIA 
ANEMIC HEALTHY 
COUNT 
MEAN 
(millions/cu.
mm) 
COUNT 
MEAN 
(millions/cu.
mm) 
 
Male 9 3.01 15 4.75 
 
Female 20 2.81 56 4.03 
 
• The mean Red Blood Corpuscles (RBC) count in anemic 
population- male is 3.01 million/ mm3 
• The mean Red Blood Corpuscles (RBC) count in anemic 
population-female is 2.81 million/ mm3 
• The mean Red Blood Corpuscles (RBC) count in healthy male 
population is 4.75 million/ mm3  
• The mean Red Blood Corpuscles (RBC) count in healthy female 
population is 4.03 million/ mm3.  
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SEX 
Hb 
ANEMIC HEALTHY 
COUNT MEAN (g/dL) COUNT 
MEAN 
(g/dL) 
Male 10 7.72 14 14.21 
Female 40 7.26 36 13.51 
 
 
The analysis of results shows that 
• The mean value of Hb in anemic male population is 7.72 g/dL. 
• The mean value of Hb in anemic female population is 7.26 g/dL. 
• The mean value of Hb in healthy male population is 14.21 g/dL. 
• The mean value of Hb in healthy female population is 13.51 g/dL. 
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• The mean value of Mean Corpuscular Volume (MCV) in anemic 
population is 69.92 fl & healthy population is 91.20 fl 
• The mean value of Mean Corpuscular Hemoglobin (MCH) in anemic 
population is 26.7 pg & in healthy population is 30.5 pg. 
• The mean value of Mean Corpuscular Hemoglobin concentration 
(MCHC) in anemic population is 33.5 g/dL & in healthy  population 
is 38.5 g/dL. 
• The mean value of Red Cell Distribution width (RDW) in anemic 
population is  19.65& in healthy population is 13.21. 
• The difference in the parameters between the groups is significant 
  Mean±S.D P VALUE 
MCV(fL) 
Anemic (n=50) 69.62±3.17 
 P<0.001 
Healthy(n=50) 91.20±3.67 
MCH(pg) 
Anemic (n=50) 26.77±5.562 
P<0.001 
Healthy (n=50) 30.50±2.71 
MCHC(g/dL) 
Anemic (n=50) 38.50±7.93 
P<0.001 
Healthy (n=50) 33.50±3.19 
RDW 
Anemic (n=50) 19.65±2.88 
P<0.001 
Healthy (n=50) 13.21±0.68 
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OTHER BLOOD CELL PARAMETERS AND ANEMIA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
•    The above table shows the mean platelets in anemic population 
is 3.22 lakhs/mm3 which is not stastically significant from that of 
the mean platelets in healthy population which is 2.95 lakhs/mm3. 
 
•     This table shows the mean White Blood Cell (WBC) count in 
anemic population 6,950cells/mm3 not differing significantly 
from that of the healthy population's value of 6,796 cells / mm3. 
 
 
 
 
 Hb MEAN ±S.D. P VALUE 
PLATELETS 
(lakhs/mm3) 
Anemic 3.22±0.83 
P>0.05 
 
Healthy 
 2.95±0.94 
WBC 
(cells/mm3) 
Anemic 6950.00±1792.76 
Healthy 
 6796.00±1752.08 
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 FASTING, POST PRANDIAL BLOOD SUGAR AND ANEMIA 
 
 
 
 
  
 
 
 
From the results, it can be inferred that 
• The mean fasting blood sugar in the anemic population  is 78.72 
mg/dL and healthy population  is 81.14 mg/dL. 
• The mean post prandial blood sugar in the anemic population is 
124.68 mg/dl and the healthy population is 126.32 mg/dl. 
• It is to be noted that FBS and PPBS did not significantly vary 
between anemic and healthy groups. 
 
  
 
 
 ANEMIA N MEAN S.D P VALUE 
FASTING BLOOD SUGAR 
(FBS) (mg/dL) 
Anemic 50 78.72 10.14 
>0.05 
 
Healthy 50 81.14 7.81 
POSTPARANDIALBLOOD 
SUGAR (PPBS) (mg/dL) 
Anemic 50 124.68 8.96 
Healthy 50 126.32 8.43 
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  ANEMIA AND HbA1c  
 ANEMIA N MEAN S.D P VALUE 
HBA1C(%) 
Anemic 50 5.3248 .32798 
0.043 
Healthy 50 5.1440 .53190 
 
• The above table shows the mean HbA1c values in anemic and healthy 
population. 
• It shows that mean Hba1c in anemic population is 5.32%±0.32. The 
mean Hba1c in healthy non anemic population is 5.14%±0.53.  
• The difference in two mean values is statistically significant. 
(p<0.05) 
 
 
5.05
5.1
5.15
5.2
5.25
5.3
5.35
anemia healthy
Hb
A1
c(
%
)
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ANEMIA AND ABSOLUTE HbA1c 
 
 ANEMIA N MEAN S.D P VALUE 
Absolute 
HBA1C 
Anemic 50 .6372 .09474 
 
>0.05 
Healthy 50 .7042 .07299 
 
•  It shows that mean absolute HbA1c in anemic population 
is0.63±0.09.The mean absolute HbA1c in healthy non anemic 
population is 0.70±0.07.  
•  The difference in two mean values are not statistically significant 
(p>0.05).  
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DISCUSSION 
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DISCUSSION 
  
 Demographic and clinical characteristics of our study population 
are that  majority of the anemics  (27 %) are in  the 12- 20 years age 
group and least in the group above 60 years. This is in concordance 
with the study conducted by Ramesh Chellan et al37.He has stated that 
severe anemia is highly prevalent in India and the prevalence is highest 
in adolescent girls. Majority of the individuals involved were females, 
with 76 participants being female. This is also in concordance with the 
studies conducted by Segun et al and Ramesh Chelan.  
  
 The predominant groups of anemic individuals involved were 
students- adolescent females.  But no stratification of severity of 
anemia was attempted in this study. Hence the prevalence of severe 
anemia in this group of individuals could not be studied.  
  
 The study comprised of 76 female and 24 male participants. The 
increased number of female participants included in the study can be 
explained by the wide prevalence of anemia among women due to 
various reasons. 
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 Menorrhagia was not a significant contributor to anemia in this 
study as only 25 anemic women had menorrhagia. The rest of the 22 
women with menorrhagia were healthy. Similarly 15 anemic patients 
involved in this study had no menorrhagia. This is in contrary to the 
study by Chappal A, according to whom menorrhagia is a significant 
contributor to anemia in women of reproductive age. 
  
 The lower mean BMI in the anemic group can be explained as 
this study included patients with moderate to severe anemia (<10 g% 
Hb) and the cause and effect of anemia on BMI could be taken as the 
probable explanation.  
  
 The two groups - students and employed people having a higher 
percentage of anemia reflect the burden of anemia on the work force  
the society. The participants included in the study belonged to the 
out-patient and inpatient department of our hospital. They can be 
taken as a representative sample of the general population. Thus the 
results can be generalized to the population.  
  
94 
 
 The mean Hb of anemia in male and female population is 7.72     
g/dL and 7.26 g/dL respectively. These values were much lower than 
when compared to the mean Hb values calculated inthe studies of  
Shanthi et al , Segun et al, Hardikar et al. Of these studies comparison 
with Shanthi et al study is significant as it was conducted in the same 
city representing a similar population. Much lower values of Hb can be 
explained on the basis of involvement of more people from lower 
socio- economic status and the study population involving Inpatients 
who are probably severely anemic.  
  
 The mean MCV values were 69.6 fl and 91.2fl in anemic and 
healthy population respectively. These were almost similar to the 
values of 72.3 fl and 84.2 fl observed in Shanthi et al study. It was 
different from the mean value of MCV which was 85 fl and 87.8 fl in 
Hardikar et al study. However all the studies had involved population 
with microcytic hypochromic anemia.  
  
 The mean MCH in anemic and healthy population was 26.7 pg 
and 30.5 pg  respectively. The mean MCH observed were 27.9, 22.6 
and 28.6, 32.9pg in the above studies.  
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 The difference in the mean HbA1c values between anemic and 
healthy population was stastically significant (P value 0.043) .This is 
in concordance with the observation by Shanthi et al, Hardikar et al, 
and Son et al. They had all observed a modest increase of HbA1c in 
anemic population. They postulated that iron deficiency causes 
increased glycation leading to spuriously high values of HbA1c. This 
is different from the observation by Nitin Sinha et al and Ford et al 
who have shown that mean HbA1c is decreased in anemic population.  
  
 Absolute HbA1c values were not significantly different between 
anemic and healthy participants. This is in concordance with the 
observation by Sinha et al . It was the first and only study which has 
correlated absolute HbA1c and anemia and that has been confirmed by 
the present study.  
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CONCLUSION 
• There is no stastically significant association between age and 
anemia in this study. 
•  Anemia group has significantly lower mean BMI than healthy group.   
•   There is no stastically significant association between menorrhagia 
and anemia in the participants of the study.  
•   There is no significant association between dietary habits and 
anemia though the proportion of anemic patients among the 
vegetarian group is high.  
• All the anemic patients included in the study were microcytic 
hypochromic anemic patients. The Hb, MCV, MCH, MCHC, RBC 
count values in anemic patients were low when compared to the 
healthy controls and the difference was stastically significant.  
• RDW indicating poikilocytosis was higher in the anemic patients 
as compared to healthy controls.  
• There was a significant difference in the mean values of HbA1c 
between anemic and healthy populations. Mean value of HbA1c in 
anemic population was significantlyhigher than the mean Hba1c 
value in healthy controls at  p value 0.043 . This can cause 
diagnostic difficulties in detecting uncontrolled diabetes mellitus 
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in iron deficient diabetic population.  
• Absolute HbA1c values corrected for anemia did not differ 
significantly in two groups.   
• Fasting and post prandial blood sugar values did not differ 
significantly in both the groups. Thus the difference in HbA1c 
could be attributed to the presence of microcytic anemia.  
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LIMITATIONS OF THE STUDY 
• The sample size was small.  
• Majority of the individuals involved in the study was younger 
population. A study involving equal distribution of participants in 
various age groups  would have thrown light upon other factors 
operating in the elderly individuals. 
• Number of females outnumbered the males in this study. 
• A confirmatory test for iron deficiency like serum ferritin was not 
applied in this study. A broad label of microcytic hypochromic 
anemia is used.  
• The study was a case control study. No effort was made at 
correcting anemia and henceforth the changes in the trend were not 
observed. 
      Further studies involving a larger population where the limitations   
      of this study are duly taken into consideration are needed 
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     QUESTIONNAIRE 
NAME: 
AGE: 
SEX: 
HEIGHT: 
WEIGHT: 
BMI: 
H/O MENORRHAGIA 
OCCUPATION: 
DIET  
INVESTIGATIONS:  
HAEMOGLOBIN LEVELS: 
MCV: 
MCH: 
MCHC: 
RDW: 
 PLATELETS: 
ERYTHROCYTES: 
WBC: 
SERUM FASTING AND POSTPRANDIAL GLUCOSE LEVELS: 
SERUM CREATININE 
HBA1C: 
ABSOLUTE HBA1C 
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